MedTrace Logo

Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia

NCT05157100 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-10-06

No results posted yet for this study

Summary

Study of Ingrezza (Valbenazine) for the treatment of cervical dystonia.

Conditions

  • Cervical Dystonia

Interventions

DRUG

Ingrezza Pill

Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.

Sponsors & Collaborators

  • The Orthopedic Foundation

    lead OTHER

Principal Investigators

  • Martin Taylor, DO, PHD · principle investigator

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2023-09-15
Completion
2023-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05157100 on ClinicalTrials.gov